Intercept Pharmaceuticals to Conduct One-on-One Meetings with Investors at the Citi 17th Annual BioPharma Conference September 8, 2022

Rhea-AI Impact

(Neutral)

Rhea-AI Sentiment

(Neutral)

Tags

08/29/2022 - 08:00 AM

MORRISTOWN, N.J., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it will be participating in investor meetings at the Citi 17th Annual BioPharma Conference at the Four Seasons Hotel in Boston on September 8, 2022.

Meeting Details
For investors attending the conference who wish to meet with the Intercept management team, please reach out to Nareg Sagherian at Intercept to check the team’s availability.

About Intercept
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). For more information, please visit www.interceptpharma.com or connect with the company on Twitter and LinkedIn.

Contact
For more information about Intercept, please contact:

Investor inquiries: investors@interceptpharma.com
Media inquiries: media@interceptpharma.com

Intercept Pharmaceuticals, Inc.

NASDAQ:ICPT

ICPT Rankings

N/A Ranked by Market Cap

N/A Ranked by Dividends

ICPT Latest News

Feb 29, 2024

Intercept Announces FDA Acceptance of Supplemental New Drug Application for Ocaliva® (obeticholic acid) for the Treatment of PBC

Nov 13, 2023

Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage at AASLD The Liver Meeting® 2023

Nov 10, 2023

Intercept Announces New Findings from Long-term Extension of Landmark POISE Trial in PBC Showing Importance of Biomarkers Beyond ALP at AASLD The Liver Meeting® 2023

Nov 8, 2023

Alfasigma completes acquisition of Intercept Pharmaceuticals, Inc.

Nov 8, 2023

Alfasigma S.p.A. successfully completes tender offer for all outstanding shares of common stock of Intercept Pharmaceuticals, Inc.

ICPT Stock Data

Market Cap 794.69M

Float 34.49M

Insiders Ownership 3.13%

Institutions Ownership 81.3%

Short Percent 24.24%

Industry Pharmaceutical Preparation Manufacturing

Sector Manufacturing

Website Link

Country United States

City Morristown

About ICPT

we are a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive, non-viral liver diseases, including primary biliary cholangitis (pbc), nonalcoholic steatohepatitis (nash), primary sclerosing cholangitis (psc) and biliary atresia. in a new age of liver disease treatment, our team is developing vital therapies to meet the needs of those living with progressive, non-viral liver disease. we are committed to improving patients’ lives and addressing the liver community’s most pressing needs. our corporate headquarters is located in new york, and we have additional offices in san diego, london and perugia. for more information about intercept, please visit our website at: www.interceptpharma.com and follow us on twitter at: @interceptpharma.

Trending News